Mechanistic systems modeling to guide drug discovery and development

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 116-127

  Schmidt, Brian J ^a   Papin, Jason A ^b   Musante, Cynthia J ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b University of Virginia   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; BIOLOGICAL MARKER; DALCETRAPIB; TORCETRAPIB;

BIOINFORMATICS; BIOTECHNOLOGY; CLINICAL RESEARCH; DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; MECHANISTIC SYSTEMS MODEL; MODEL; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SIMULATION; SYSTEMS BIOLOGY; UNCERTAINTY;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; RESEARCH;

EID: 84873093745     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.09.003     Document Type: Review

References (131)

1. H. Kubinyi Success stories of computer-aided design S. Ekins, Computer Applications in Pharmaceutical Research and Development 2006 John Wiley & Sons, Inc.
2. G.H. Fernald Bioinformatics challenges for personalized medicine Bioinformatics 27 2011 1741 1748
3. S.N. Khleif AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development Clin. Cancer Res. 16 2010 3299 3318
4. M.A. Oberhardt Applications of genome-scale metabolic reconstructions Mol. Syst. Biol. 5 2009 320
5. S. Michelson Target identification and validation using human simulation models D. León, S. Markel, In Silico Technologies in Drug Target Identification and Validation Vol. 6 2006 CRC Press/Taylor & Francis Group
6. C.J. Musante Small- and large-scale biosimulation applied to drug discovery and development Drug Discov. Today 7 20 Suppl. 2002 S192 S196
7. S. Aslam Biosimulation: advancements in the pathway of drug discovery and development IJPSR 3 2010 99 105
8. R.N. Bergman Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose J. Clin. Invest. 68 1981 1456 1467
9. R.N. Bergman Quantitative estimation of insulin sensitivity Am. J. Physiol. 236 1979 E667 E677
10. R.N. Bergman The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes Eur. J. Clin. Invest. 32 Suppl. 3 2002 35 45
11. D.A. D'Alessio Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I Diabetes 44 1995 1433 1437
12. ADA Guidelines for computer modeling of diabetes and its complications Diabetes Care 27 2004 2262 2265
13. L. Shoda The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse Clin. Exp. Immunol. 161 2010 250 267
14. S. Michelson In silico prediction of clinical efficacy Curr. Opin. Biotechnol. 17 2006 666 670
15. R.N. Gutenkunst Universally sloppy parameter sensitivities in systems biology models PLoS Comput. Biol. 3 2007 1871 1878
16. J.A. DiMasi The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 151 185
17. C.P. Adams, and V.V. Brantner Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood) 25 2006 420 428
18. J.A. Dimasi New drug development in the United States from 1963 to 1999 Clin. Pharmacol. Ther. 69 2001 286 296
19. C. Friedrich Comparison of NLME and mechanistic physiological modeling methods using examples in drug discovery and development American Conference on Pharmacometrics San Diego, USA, April 3-10 2011
20. C. Friedrich Comparison of statistical and physiological modeling methods using examples in drug discovery and development Population Approach Group in Europe Athens, Greece, June 7-10 2011
21. C.C. Gallen Strategic challenges in neurotherapeutic pharmaceutical development NeuroRx 1 2004 165 180
22. J.A. Rullmann Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform IEEE Proc. Syst. Biol. 152 2005 256 262
23. N.C. Duarte Global reconstruction of the human metabolic network based on genomic and bibliomic data Proc. Natl. Acad. Sci. U. S. A. 104 2007 1777 1782
24. D.B. Kell Systems biology, metabolic modelling and metabolomics in drug discovery and development Drug Discov. Today 11 2006 1085 1092
25. J.L. Reed Towards multidimensional genome annotation Nat. Rev. Genet. 7 2006 130 141
26. M. Durot Genome-scale models of bacterial metabolism: reconstruction and applications FEMS Microbiol. Rev. 33 2009 164 190
27. A.M. Feist Reconstruction of biochemical networks in microorganisms Nat. Rev. Microbiol. 7 2009 129 143
28. K. Raman, and N. Chandra Flux balance analysis of biological systems: applications and challenges Brief. Bioinform. 10 2009 435 449
29. N. Jamshidi, and B.O. Palsson Mass action stoichiometric simulation models: incorporating kinetics and regulation into stoichiometric models Biophys. J. 98 2010 175 185
30. J. Schellenberger BiGG: a Biochemical Genetic and Genomic knowledgebase of large scale metabolic reconstructions BMC Bioinformatics 11 2010 213
31. M.L. Mo A genome-scale, constraint-based approach to systems biology of human metabolism Mol. Biosyst. 3 2007 598 603
32. T. Shlomi Network-based prediction of human tissue-specific metabolism Nat. Biotechnol. 26 2008 1003 1010
33. A. Bordbar Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions Mol. Syst. Biol. 6 2010 422
34. A. Bordbar Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation Mol. Syst. Biol. 8 2012 558
35. R.L. Chang Drug off-target effects predicted using structural analysis in the context of a metabolic network model PLoS Comput. Biol. 6 2010 E1000938
36. N.E. Lewis Large-scale in silico modeling of metabolic interactions between cell types in the human brain Nat. Biotechnol. 28 2010 1279 1285
37. L. Jerby Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism Mol. Syst. Biol. 6 2010 401
38. A. Bordbar iAB-RBC-283: a proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states BMC Syst. Biol. 5 2011 110
39. H. Ma The Edinburgh human metabolic network reconstruction and its functional analysis Mol. Syst. Biol. 3 2007 135
40. C. Gille HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology Mol. Syst. Biol. 6 2010 411
41. R. Agren Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT PLoS Comput. Biol. 8 2012 E1002518
42. A. Bordbar A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology BMC Syst. Biol. 5 2011 180
43. L.B. Edelman In silico models of cancer Wiley Interdiscip. Rev. Syst. Biol. Med. 2 2010 438 459
44. O. Folger Predicting selective drug targets in cancer through metabolic networks Mol. Syst. Biol. 7 2011 517
45. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
46. J.C. LaRosa Intensive lipid lowering with atorvastatin in patients with stable coronary disease N. Engl. J. Med. 352 2005 1425 1435
47. A.R. Tall The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27 2007 257 260
48. P.J. Barter Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122
49. L.M. Powell Application of predictive biosimulation to the study of atherosclerosis: development of the Cardiovascular PhysioLab platform and evaluation of CETP inhibitor therapy FOSBE 2007 2007 295 302
50. K. Wahba Clinical trial simulations of dyslipidemic patients in a mechanistic model of cardiovascular disease predict little impact on CHD events by CETP inhibitors AHA Scientific Sessions 2011
51. G.G. Schwartz Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am. Heart J. 158 2009 896-901.e3
52. C.P. Cannon Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am. Heart J. 158 2009 513-519.e3
53. L. Xie Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors PLoS Comput. Biol. 5 2009 E1000387
54. E.A. Stein Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur. Heart J. 31 2010 480 488
55. E.A. Stein Safety and tolerability of dalcetrapib Am. J. Cardiol. 104 2009 82 91
56. J.G. Robinson Dalcetrapib: a review of Phase II data Expert Opin. Investig. Drugs 19 2010 795 805
57. R. Krishna Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
58. D. Bloomfield Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am. Heart J. 157 2009 352-360.e2
59. C.P. Cannon Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
60. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition J. Pharm. Sci. 91 2002 1358 1370
61. W.C. Hwang Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery Clin. Pharmacol. Ther. 84 2008 563 572
62. S.I. Berger, and R. Iyengar Network analyses in systems pharmacology Bioinformatics 25 2009 2466 2472
63. S.I. Berger, and R. Iyengar Role of systems pharmacology in understanding drug adverse events Wiley Interdiscip. Rev. Syst. Biol. Med. 3 2011 129 135
64. R. Mahajan, and K. Gupta Food and drug administration's critical path initiative and innovations in drug development paradigm: challenges, progress, and controversies J. Pharm. Bioallied Sci. 2 2010 307 313
65. A. von Eckardstein Mulling over the odds of CETP inhibition Eur. Heart J. 31 2010 390 393
66. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
67. M.P. Gulseth Ximelagatran: an orally active direct thrombin inhibitor Am. J. Health Syst. Pharm. 62 2005 1451 1467
68. M.R. Vickers Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women BMJ 335 2007 239
69. C.M. Meeuwisse Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint Arthritis Rheum. 63 2011 1265 1273
70. T. Shlomi Predicting metabolic biomarkers of human inborn errors of metabolism Mol. Syst. Biol. 5 2009 263
71. J.A. DiMasi The value of improving the productivity of the drug development process: faster times and better decisions Pharmacoeconomics 20 Suppl. 3 2002 1 10
72. F. Pammolli The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
73. C. Kaleta In silico evidence for gluconeogenesis from fatty acids in humans PLoS Comput. Biol. 7 2011 E1002116
74. M.I. Sigurdsson Genome-scale network analysis of imprinted human metabolic genes Epigenetics 4 2009 43 46
75. M.I. Sigurdsson A detailed genome-wide reconstruction of mouse metabolism based on human Recon 1 BMC Syst. Biol. 4 2010 140
76. A.E. Motter Improved network performance via antagonism: from synthetic rescues to multi-drug combinations Bioessays 32 2010 236 245
77. Z. Li Two-stage flux balance analysis of metabolic networks for drug target identification BMC Syst. Biol. 5 Suppl. 1 2011 S11
78. Z. Li Drug target identification based on flux balance analysis of metabolic networks International Conference on Computational Systems Biology 2010 331 338
79. Y.K. Oh Genome-scale reconstruction of metabolic network in Bacillus subtilis based on high-throughput phenotyping and gene essentiality data J. Biol. Chem. 282 2007 28791 28799
80. S. Mintz-Oron Network-based prediction of metabolic enzymes' subcellular localization Bioinformatics 25 2009 i247 i252
81. A. Bordbar, and B.O. Palsson Using the reconstructed genome-scale human metabolic network to study physiology and pathology J. Intern. Med. 271 2012 131 141
82. A. Bangs Predictive biosimulation and virtual patients in pharmaceutical R and D Stud. Health Technol. Inform. 111 2005 37 42
83. A.M. Gonzalez-Angulo Future of personalized medicine in oncology: a systems biology approach J. Clin. Oncol. 28 2010 2777 2783
84. K. Moore Use of a large biological model with single-dose clinical data to predict hemoglobin (Hb) response in patients with anemia American Conference on Pharmacometrics San Diego, USA, April 3-6 2011
85. C. Stokes Biological systems modeling: powerful discipline for biomedical e-R&D AIChE J. 46 2000 430 433
86. C.L. Stokes A computer model of chronic asthma with application to clinical studies: example of treatment of exercise-induced asthma J. Allergy Clin. Immunol. 107 2001 A933
87. A.K. Lewis The role of beta2-adrenergic receptor polymorphisms in clinical outcomes following chronic beta2-agonist use Am. J. Respir. Crit. Care Med. 163 2001 A143
88. L. Li Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines BMC Bioinformatics 11 2010 501
89. C. Frezza Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase Nature 477 2011 225 230
90. T. Shlomi Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect PLoS Comput. Biol. 7 2011 E1002018
91. N. Ambert Computational studies of NMDA receptors: differential effects of neuronal activity on efficacy of competitive and non-competitive antagonists Open Access Bioinformatics 2 2010 113 125
92. S.B. Waters Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion J. Diabetes Sci. Technol. 3 2009 68 82
93. A.R. Kansal, and J. Trimmer Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design IEEE Proc. Syst. Biol. 152 2005 214 220
94. J. Timmer Systems biology of mammalian cells: a report from the Freiburg conference Bioessays 32 2010 1099 1104
95. T.D. Vo Systems analysis of energy metabolism elucidates the affected respiratory chain complex in Leigh's syndrome Mol. Genet. Metab. 91 2007 15 22
96. H.U. Kim Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE Mol. Biosyst. 6 2010 339 348
97. N. Jamshidi, and B.O. Palsson Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets BMC Syst. Biol. 1 2007 26
98. D.J. Beste GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism Genome Biol. 8 2007 R89
99. X. Fang A systems biology framework for modeling metabolic enzyme inhibition of Mycobacterium tuberculosis BMC Syst. Biol. 3 2009 92
100. X. Fang Modeling synergistic drug inhibition of Mycobacterium tuberculosis growth in murine macrophages Mol. Biosyst. 7 2011 2622 2636
101. K. Fang Exploring the metabolic network of the epidemic pathogen Burkholderia cenocepacia J2315 via genome-scale reconstruction BMC Syst. Biol. 5 2011 83
102. A. Raghunathan Systems approach to investigating host-pathogen interactions in infections with the biothreat agent Francisella. Constraints-based model of Francisella tularensis BMC Syst. Biol. 4 2010 118
103. A.K. Chavali Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major Mol. Syst. Biol. 4 2008 177
104. A.K. Chavali Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease BMC Syst. Biol. 6 2012 27
105. H.U. Kim Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery Mol. Syst. Biol. 7 2011 460
106. M.A. Oberhardt Genome-scale metabolic network analysis of the opportunistic pathogen Pseudomonas aeruginosa PAO1 J. Bacteriol. 190 2008 2790 2803
107. D.S. Lee Comparative genome-scale metabolic reconstruction and flux balance analysis of multiple Staphylococcus aureus genomes identify novel antimicrobial drug targets J. Bacteriol. 191 2009 4015 4024
108. A. Raghunathan Constraint-based analysis of metabolic capacity of Salmonella typhimurium during host-pathogen interaction BMC Syst. Biol. 3 2009 38
109. A. Lo Using a systems biology approach to explore hypotheses underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies H. Kimko, C. Peck, Clinical Trial Simulations: Applications and Trends Vol. 1 2011 Springer 457 482
110. K. Hallow A systems modeling approach to understanding the mechanisms of renal protection observed in the avoid study: 5C.02 20th European Meeting on Hypertension (Vol. 28) 2010 E225
111. N.A. Defranoux In silico modeling and simulation of bone biology: a proposal J. Bone Miner. Res. 20 2005 1079 1084
112. R.N. Hansen In silico target evaluation of NKG2D for treatment of rheumatoid arthritis EULAR Annual European Congress of Rheumatology London, UK, May 25-28 2011
113. S. Chang Mathematical model predicting outcomes of sepsis patients treated with xigris: enhance trial Shock 25 S16 2006 70 71
114. J. Sarkar Mathematical modeling of community-acquired pneumonia patients Crit. Care 13 S4 2009 P49
115. D. Marathe Modeling of severe sepsis patients with community acquired pneumonia Shock 33 S1 2010 72 73
116. S.M. Keating SBMLToolbox: an SBML toolbox for MATLAB users Bioinformatics 22 2006 1275 1277
117. J. Schellenberger Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 Nat. Protoc. 6 2011 1290 1307
118. R. Ho Chronic inflammation in asthma airway remodeling 15th International Conference of the Inflammation Research Association Chantilly, USA, September 21-24 2008
119. T.H. Han Alteration of glucose and insulin regulatory networks in Type 2 diabetes mellitus 17th Annual Meeting of the Population Approach Group in Europe Marseille, France, June 18-20 2008
120. R. Baillie Modeling glucose metabolism in diabetes Cambridge Health Institute Discovery on Target Boston, USA, November 2-4 2010
121. A. Ghosh A systems approach to accelerating the pharmaceutical industry pipeline: competitive preclinical and clinical modeling in diabetes drug development Cambridge Health Institute Discovery on Target Boston, USA, November 2-4 2010
122. D. Tess Impact of modeling on GPR119 agonist development American Conference on Pharmacometrics San Diego, USA, April 3-6 2011
123. D. Tess, and R. Baillie Creating and using a physiological model to support development of a GPR119 agonist diabetes therapy Biorbis World PK/PD Summit Boston, USA, April 26-29 2011
124. M. Akesson Integration of gene expression data into genome-scale metabolic models Metab. Eng. 6 2004 285 293
125. H. Zur iMAT: an integrative metabolic analysis tool Bioinformatics 26 2010 3140 3142
126. S.A. Becker, and B.O. Palsson Context-specific metabolic networks are consistent with experiments PLoS Comput. Biol. 4 2008 E1000082
127. C. Colijn Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production PLoS Comput. Biol. 5 2009 E1000489
128. K. Yizhak Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model Bioinformatics 26 2010 i255 i260
129. R.J.P. van Berlo Predicting metabolic fluxes using gene expression differences as constraints IEEE/ACM Trans. Comput. Biol. Bioinform. 8 2011 206 216
130. P.A. Jensen, and J.A. Papin Functional integration of a metabolic network model and expression data without arbitrary thresholding Bioinformatics 27 2011 541 547
131. P.A. Jensen TIGER: toolbox for integrating genome-scale metabolic models, expression data, and transcriptional regulatory networks BMC Syst. Biol. 5 2011 147